TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06365424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate (200 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: Ursodeoxycholic acid (13-15 mg/kg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: Ursodeoxycholic acid (13-15 mg/kg/day)
Study: NCT04103619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuTite
Description: Subjects will undergo treatment with AccuTite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuTite + Morpheus 8
Description: Subjects will undergo treatment with AccuTite and Morpheus 8
Study: NCT01749215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Experimental study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management
Description: Brief alcohol counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Brief alcohol counseling
Study: NCT02874872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OASIS Collaborative
Description: OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
Study: NCT01162096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haploidentical Allogeneic Transplantation
Description: Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
Study: NCT02049034

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
Study: NCT00926549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
Description: macular cube scanning
Study: NCT03435003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg Oral Capsule
Description: aprepitant 80 mg orally one hour prior to scheduled surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine transdermal
Description: scopolamine transdermal patch one hour prior to scheduled surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Description: Maintenance of anesthesia without the use of inhaled anesthetics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg intraoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reglan
Description: Postoperatively scheduled Reglan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reglan
Description: Postoperatively scheduled Reglan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Postoperatively scheduled ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Postoperatively scheduled ondansetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compazine
Description: Postoperatively as needed compazine for breakthrough PONV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compazine
Description: Postoperatively as needed compazine for breakthrough PONV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Reversal with sugammadex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Reversal with sugammadex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous anesthesia will be maintained through IV propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: maintenance of anesthesia in the intervention arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhalational anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: inhalational anesthesia
Study: NCT04631627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin
Description: With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
Study: NCT01409616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban (double dose)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban (double dose)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban (double dose)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban (double dose)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: oral
Study: NCT00222053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Per os thalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphosphonates
Description: Biphosphonates
Study: NCT01544699

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS (ELDITH)
Description: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (ELDITH)
Description: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
Study: NCT03695315

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: CPAP is a noninvasive treatment for sleep apnea

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: CPAP is a noninvasive treatment for sleep apnea
Study: NCT02665065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iomab-B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HCT
Study: NCT01944735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-4430
Description: Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
Study: NCT04160143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection and stereotactic body radiation therapy (SBRT)
Description: Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
Study: NCT03146468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
Study: NCT00652392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: budesonide and placebo
Study: NCT01508546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary dissection
Description: Conservative breast surgery with or without axillary dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary dissection
Description: Conservative breast surgery with or without axillary dissection
Study: NCT04283266

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
Study: NCT04066803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDs
Description: including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
Study: NCT02815917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTP PET/CT
Description: All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTP PET/CT
Description: All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTP PET/CT
Description: All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTP PET/CT
Description: All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.
Study: NCT01436071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50mcg
Description: Inhalation powder delivered by Novel Dry Powder Inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation powder delivered by Novel Dry Powder Inhaler
Study: NCT04026139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Band Resistance Exercise
Description: Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active joint range-of-motion exercises and isometric contraction exercises
Description: The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.
Study: NCT01955122

Intervention type: DEVICE
Group type: OTHER
Intervention: Tandem Colonoscopy
Description: Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.

Intervention type: DEVICE
Group type: OTHER
Intervention: Tandem Colonoscopy
Description: Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
Study: NCT01762176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized intensive treatment
Description: Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
Study: NCT02445196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Coach
Description: PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Coach
Description: PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: All participants must have a smartphone, either apple or android.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: All participants must have a smartphone, either apple or android.
Study: NCT01728220

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled NO delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled NO delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled NO delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled NO delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled NO delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
Study: NCT01195545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veritas® Collagen Matrix
Description: biological mesh in hernia repair
Study: NCT04264429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrapatellar strap
Description: Orthotic device which is positioned over the patellar tendon

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic band
Description: Orthotic device which is positioned over the patellar tendon
Study: NCT04586595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REVISiT intervention
Description: REVISiT is a pharmacist-led retrospective review of prescribing followed by a feedback meeting to discuss the review findings.
Study: NCT00910351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro, BAYQ3939)
Description: 25 mg inhaled Ciprofloxacin
Study: NCT01721005

Intervention type: OTHER
Group type: OTHER
Intervention: Subject education to pulse palpation
Description: The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
Study: NCT02915471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Peer-to-Peer Support Mentoring
Description: The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
Study: NCT01215175

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114, Aluminum Adjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114, Aluminum Adjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114, Aluminum Nonadjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
Study: NCT01028222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib was provided as 200 mg hard gelatin capsules for oral use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC
Description: DTIC was supplied locally as sterile powder for i.v. infusion.
Study: NCT00510250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40mg/m2 administered weekly via IV, with Radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.